5th Ophthalmic Drug Delivery Summit

The 5th Ophthalmic Drug Delivery Summit is where the innovators behind the next generation of ocular therapies come together to solve one critical challenge: getting the right therapy to the right place in the eye.

Hear directly from leaders at Kodiak Sciences, Re-Vana Therapeutics, Ripple Therapeutics, Eli Lilly, Genentech, Sanofi, Astellas, Apellis, Beacon Therapeutics, Kriya Therapeutics and more as they share the latest thinking on long-acting therapies, novel delivery routes, gene and cell therapy, translational science and drug-device integration.

With clinical validation and investment accelerating across the field, this industry-focused, modality and indication-agnostic meeting offers a timely opportunity to benchmark emerging technologies, learn from development successes and setbacks, and connect with the experts tackling the biggest barriers to effective ocular delivery.

Expect candid lessons, emerging strategies and cross-functional perspectives spanning delivery, formulation, devices, CMC, clinical development, regulatory strategy and commercialization.

URLs:
Website: https://go.evvnt.com/3822848-0?pid=2874
Brochure: https://go.evvnt.com/3822848-3?pid=2874

Prices:
Industry Pricing - 3 Day Pass - (Conference + Workshop Day): USD 4607.00,
Industry Pricing - 2 Day Pass - (Conference Only): USD 3149.00,
Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 4007.00,
Academic Pricing - 2 Day Pass (Conference Only): USD 2749.00,
Service Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 4957.00,
Service Provider Pricing - 2 Day Pass (Conference Only): USD 3699.00

Speakers: Stephen Poor, Head of Translational Medicine, Apellis Pharmaceuticals, Hemant Khanna, Lead, Ophthalmology Strategy, Astellas Pharma, Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Ajit D'Souza, Executive Director, Drug Delivery and Devices, Eli Lilly and Co, Moshe Weinstein, Executive Chairman, Everads-Therapy, Max Cotler, Chief Executive Officer, GelMEDIX, Justin Creel, Executive Director, Device Development, Genentech, Kirsten Cummiskey, Senior Principal Engineer, Genentech, Fernando Correa, Executive Director, Kodiak Sciences, Viral Kansara, Chief Discovery and Development Advisor, NeuParadigmBio, Raj Patil, Chief Scientific Officer, OKYO Pharma, Maryam Mokhtarzadeh, Chief Medical Officer, Persephoni Biosciences, Cyndi Lee, Program Management, Re-Vana Therapeutics, Patrick Ruane, Chief Operating Officer, Re-Vana Therapeutics, Wendy Naimark, Chief Technology Officer and Co Founder, Ripple Therapeutics, Pavitra Ramachandran, Head of Ocular In Vivo Translational Sciences, Sanofi, Ajay Khopade, Vice President, Head of Formulation Non-Orals and Analytical, and RandD Site Head, Sun Pharmaceutical Industries, Daniel Chao, Vice President and Head of Clinical Development, Surrozen, David Almeida, Founder, The Centers for Advanced Surgical Exploration (CASEx), Claire Gelfman, Associate Adjunct Professor, University of California, Irvine, Department of Ophthalmology and Vision Sciences, Juan Pablo Robles, Founder, ViAn Therapeutics

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Discovery